Neurocrine Biosciences, Inc.
NBIX
$131.14
-$1.24-0.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.33% | 15.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.33% | 15.62% | |||
| Cost of Revenue | 4.47% | 3.29% | |||
| Gross Profit | -0.23% | 22.92% | |||
| SG&A Expenses | 3.74% | 1.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.09% | 2.53% | |||
| Operating Income | -5.06% | 64.35% | |||
| Income Before Tax | -17.96% | 82.95% | |||
| Income Tax Expenses | 4.13% | 58.27% | |||
| Earnings from Continuing Operations | -26.63% | 94.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.63% | 94.88% | |||
| EBIT | -5.06% | 64.35% | |||
| EBITDA | -4.98% | 61.54% | |||
| EPS Basic | -27.00% | 94.09% | |||
| Normalized Basic EPS | -3.73% | 56.71% | |||
| EPS Diluted | -27.53% | 92.45% | |||
| Normalized Diluted EPS | -4.37% | 55.03% | |||
| Average Basic Shares Outstanding | 0.50% | 0.40% | |||
| Average Diluted Shares Outstanding | 1.17% | 1.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||